{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:12:59Z","timestamp":1788441179543,"version":"build-2803163510"},"reference-count":37,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Mesenchymal stromal cell (MSC) therapy has been investigated for more than two decades as a regenerative approach in cardiovascular disease. Preclinical studies have shown reproducible biological activity; however, clinical translation has been less convincing. Trials in acute myocardial infarction (AMI) and heart failure (HF) have established feasibility and an acceptable safety profile; however, effects on functional and imaging parameters remain modest, and a consistent impact on mortality, hospitalization, and other hard clinical outcomes has not been demonstrated.<\/jats:p>","DOI":"10.31083\/rcm52521","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:17:46Z","timestamp":1788437866000},"source":"Crossref","is-referenced-by-count":0,"title":["Mesenchymal Stromal Cell Therapy in Cardiovascular Disease: Reconsidering Clinical Inconsistency Through the Mechanism\u2013Endpoint Relationship"],"prefix":"10.31083","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6360-5653","authenticated-orcid":true,"given":"Luca","family":"Bonanni","sequence":"first","affiliation":[{"name":"Department of Medicine, Ospedale dell\u2019Angelo, 30174 Venice, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1454-1687","authenticated-orcid":true,"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padua, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Psaltis PJ, Zannettino ACW, Worthley SG, Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells (Dayton, Ohio). 2008; 26: 2201\u20132210.","DOI":"10.1634\/stemcells.2008-0428"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circulation Research. 2015; 116: 1413\u20131430.","DOI":"10.1161\/CIRCRESAHA.116.303614"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circulation Research. 2011; 109: 923\u2013940.","DOI":"10.1161\/CIRCRESAHA.111.243147"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011; 9: 11\u201315.","DOI":"10.1016\/j.stem.2011.06.008"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Wang Y, Qi Z, Yan Z, Ji N, Yang X, Gao D, et al. Mesenchymal Stem Cell Immunomodulation: A Novel Intervention Mechanism in Cardiovascular Disease. Frontiers in Cell and Developmental Biology. 2022; 9: 742088.","DOI":"10.3389\/fcell.2021.742088"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012; 10: 244\u2013258.","DOI":"10.1016\/j.stem.2012.02.005"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Wu X, Jiang J, Gu Z, Zhang J, Chen Y, Liu X. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Research & Therapy. 2020; 11: 345.","DOI":"10.1186\/s13287-020-01855-9"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Vagnozzi RJ, Maillet M, Sargent MA, Khalil H, Johansen AKZ, Schwanekamp JA, et al. An acute immune response underlies the benefit of cardiac stemcell therapy. Nature. 2020; 577: 405\u2013409.","DOI":"10.1038\/s41586-019-1802-2"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Bagno L, Hatzistergos KE, Balkan W, Hare JM. Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges. Molecular Therapy: the Journal of the American Society of Gene Therapy. 2018; 26: 1610\u20131623.","DOI":"10.1016\/j.ymthe.2018.05.009"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Majka M, Su\u0142kowski M, Badyra B, Musia\u0142ek P. Concise Review: Mesenchymal Stem Cells in Cardiovascular Regeneration: Emerging Research Directions and Clinical Applications. Stem Cells Translational Medicine. 2017; 6: 1859\u20131867.","DOI":"10.1002\/sctm.16-0484"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Lalu MM, Mazzarello S, Zlepnig J, Dong YYR, Montroy J, McIntyre L, et al. Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. Stem Cells Translational Medicine. 2018; 7: 857\u2013866.","DOI":"10.1002\/sctm.18-0120"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Caplan AI. Mesenchymal Stem Cells: Time to Change the Name! Stem Cells Translational Medicine. 2017; 6: 1445\u20131451.","DOI":"10.1002\/sctm.17-0051"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Bagno LL, Salerno AG, Balkan W, Hare JM. Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method. Expert Opinion on Biological Therapy. 2022; 22: 449\u2013463.","DOI":"10.1080\/14712598.2022.2016695"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Galipeau J, Krampera M, Leblanc K, Nolta JA, Phinney DG, Shi Y, et al. Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. Cytotherapy. 2021; 23: 368\u2013372.","DOI":"10.1016\/j.jcyt.2020.11.007"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Yang H, He C, Bi Y, Zhu X, Deng D, Ran T, et al. Synergistic effect of VEGF and SDF-1\u03b1 in endothelial progenitor cells and vascular smooth muscle cells. Frontiers in Pharmacology. 2022; 13: 914347.","DOI":"10.3389\/fphar.2022.914347"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Zhang JJ, Pogwizd SM, Fukuda K, Zimmermann WH, Fan C, Hare JM, et al. Trials and tribulations of cell therapy for heart failure: an update on ongoing trials. Nature Reviews. Cardiology. 2025; 22: 372\u2013385.","DOI":"10.1038\/s41569-024-01098-8"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Li J, Hu S, Zhu D, Huang K, Mei X, L\u00f3pez de Juan Abad B, et al. All Roads Lead to Rome (the Heart): Cell Retention and Outcomes From Various Delivery Routes of Cell Therapy Products to the Heart. Journal of the American Heart Association. 2021; 10: e020402.","DOI":"10.1161\/JAHA.120.020402"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009; 5: 54\u201363.","DOI":"10.1016\/j.stem.2009.05.003"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Bonanni L, Ferri N. Mesenchymal Stem Cell-Derived Extracellular Vesicles in Myocardial Ischemia-Reperfusion Injury: A Comprehensive Review. Biology. 2026; 15: 383.","DOI":"10.3390\/biology15050383"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Pandey SN, Afzal M, Goyal K, M M R, Nayak PP, Maqbool M, et al. The role of MSC-derived exosomes in immune modulation and regenerative medicine. Journal of Drug Targeting. 2026; 1\u201319.","DOI":"10.1080\/1061186X.2026.2620707"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Bonanni L, Ferri N, Simioni P. Mesenchymal Stromal Cells at the Interface of Hemostasis and Immunothrombosis. Biology. 2026; 15: 728.","DOI":"10.3390\/biology15090728"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Attar A, Bahmanzadegan Jahromi F, Kavousi S, Monabati A, Kazemi A. Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials. Stem Cell Research & Therapy. 2021; 12: 600.","DOI":"10.1186\/s13287-021-02667-1"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Jeong H, Yim HW, Park HJ, Cho Y, Hong H, Kim NJ, et al. Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-analysis. International Journal of Stem Cells. 2018; 11: 1\u201312.","DOI":"10.15283\/ijsc17061"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow\u2013derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012; 308: 2369\u20132379.","DOI":"10.1001\/jama.2012.25321"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014; 311: 62\u201373.","DOI":"10.1001\/jama.2013.282909"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Mathiasen AB, Qayyum AA, J\u00f8rgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). European Heart Journal. 2015; 36: 1744\u20131753.","DOI":"10.1093\/eurheartj\/ehv136"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, et al. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). Circulation Research. 2017; 121: 1279\u20131290.","DOI":"10.1161\/CIRCRESAHA.117.311827"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Rendra E, Scaccia E, Bieback K. Recent advances in understanding mesenchymal stromal cells. F1000Research. 2020; 9: F1000 Faculty Rev\u2013156.","DOI":"10.12688\/f1000research.21862.1"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Costa LA, Eiro N, Fraile M, Gonzalez LO, Sa\u00e1 J, Garcia-Portabella P, et al. Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. Cellular and Molecular Life Sciences: CMLS. 2021; 78: 447\u2013467.","DOI":"10.1007\/s00018-020-03600-0"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Poomani MS, Radhakrishnan V, James SB, Muthan K, Subramanian V. Therapeutic potential of mesenchymal stem cells and their mechanisms of regeneration for cardiac diseases. Brain Heart. 2024; 2: 2065.","DOI":"10.36922\/bh.2065"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Wilson AJ, Rand E, Webster AJ, Genever PG. Characterisation of mesenchymal stromal cells in clinical trial reports: analysis of published descriptors. Stem Cell Research & Therapy. 2021; 12: 360.","DOI":"10.1186\/s13287-021-02435-1"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Wilson A, Hodgson-Garms M, Frith JE, Genever P. Multiplicity of Mesenchymal Stromal Cells: Finding the Right Route to Therapy. Frontiers in Immunology. 2019; 10: 1112.","DOI":"10.3389\/fimmu.2019.01112"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Alsultan A, Farge D, Kili S, Forte M, Weiss DJ, Grignon F, et al. International Society for Cell and Gene Therapy Clinical Translation Committee recommendations on mesenchymal stromal cells in graft-versus-host disease: easy manufacturing is faced with standardizing and commercialization challenges. Cytotherapy. 2024; 26: 1132\u20131140.","DOI":"10.1016\/j.jcyt.2024.05.007"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Pittenger MF, Discher DE, P\u00e9ault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine. 2019; 4: 22.","DOI":"10.1038\/s41536-019-0083-6"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Fran\u00e7ois M, Galipeau J. New insights on translational development of mesenchymal stromal cells for suppressor therapy. Journal of Cellular Physiology. 2012; 227: 3535\u20133538.","DOI":"10.1002\/jcp.24081"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Bartunek J, Terzic A, Davison BA, Filippatos GS, Radovanovic S, Beleslin B, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. European Heart Journal. 2017; 38: 648\u2013660.","DOI":"10.1093\/eurheartj\/ehw543"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Vassalli G, Moccetti T. Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction. Swiss Medical Weekly. 2011; 141: w13209.","DOI":"10.4414\/smw.2011.13209"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/8\/10.31083\/RCM52521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:18:17Z","timestamp":1788437897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/8\/10.31083\/RCM52521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1530-6550(26)03549-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm52521","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"52521"}}